1 Major depressive disorder (MDD) is a common and disabling syndrome with multiple 2 etiologies that is defined by clinically elicited signs and symptoms. In hopes of developing a list 3 of candidate biological measures that reflect and relate closely to the severity of depressive 4 symptoms, so-called "state-dependent" biomarkers of depression, this pilot study explored the 5 biochemical underpinnings of treatment response to cognitive behavior therapy (CBT) in 6 medication-freeMDD outpatients. Plasma samples were collected at baseline and week 12 from a 7 subset of MDD patients (N=26) who completed a course of CBT treatment as part of the 8
For statistical analysis we adopted a two-pronged approach. Initially, a multivariate "co-1 7 4
expression network" analysis was employed with CBT treated patients to detect clusters (or 1 7 5 modules) of metabolites demonstrating similar patterns of perturbations that correlated with 1 7 6 changes in depressive symptom scores based on the HAM-D 17 . Univariate analyses were also 1 7 7
performed to detect whether the metabolites within or outside the clusters were individually and 1 7 8 significantly correlated to the depressive symptom outcome. The traditional univariate analysis 1 7 9
method to metabolomic profiling focuses on the individual metabolites; thus, the interactions 1 8 0 among metabolites are largely ignored, even though it is appropriate to assume that metabolites 1 8 1 play their roles not in isolation but via interactions with each other. Consequently, metabolite 1 8 2 "co-expression" analysis is a powerful, multivariate approach to identify groups of perturbed 1 8 3 metabolites belonging to same class or pathways. This approach has the additional benefit of 1 8 4
alleviating the multiple testing problem (DiLeo et al. 2011) . The workflow of data analysis is 1 8 5 presented in Figure 1 . 1 8 6 1 8 7
Univariate Analysis: To define the association between changes in metabolite levels from 1 8 8 baseline to week 12 of CBT treatment and the changes in depressive symptom of total HAM-D 17 1 8 9 scores over that time, linear mixed effects models were fitted to each metabolite change, 1 9 0 adjusting for age and gender and with subjects as a random variable. All p-values were checked 1 9 1 for false discovery rates by Benjamini-Hochberg method (Hochberg and Benjamini 1990) . 1 9 2
Correlation between metabolite changes and depressive symptoms changes were also assessed 1 9 3
by Pearson's correlation coefficients. 1 9 4
Co-expression network analyses: Changes in modules of 'co-expressed' metabolites were 1 9 5 identified using the R package WGCNA (weighted gene co-expression network 1 9 6 analysis) (Langfelder and Horvath 2008) . Signed and weighted Pearson's correlation networks 1 9 7
were constructed with the subject-wise changes of baseline to week 12 metabolite concentrations 1 9 8
(in the logarithmic scale). First a weighted adjacency matrix was created based on pairwise 1 9 9
Pearson's correlation coefficients between the metabolites. A scale-free topology criterion was 2 0 0 used to choose the soft threshold of beta = 18 for the correlations as per the WGCNA protocol. The obtained adjacency matrix was used to calculate the topological overlap measure (TOM) for 2 0 2 each pair of metabolite log2 fold changes comparing their adjacencies with all of the other 2 0 3 metabolite log2 fold changes. Densely interconnected groups (or modules) of metabolites were 2 0 4 identified by hierarchical clustering using 1-TOM as a distance measure through the use of the 2 0 5 dynamic hybrid tree cut algorithm with a deep split of 2 and a minimum cluster size of 3. Each  2  0  6  module is summarized by the module eigenvector, which is the first principal component of the  2  0  7 metabolite changes across all the subjects. Similar clusters were subsequently merged if the 2 0 8 correlation coefficient between the clusters' eigenvectors exceeded 0.75. The association 2 0 9
between the resultant modules and the changes in HAM-D 17 scores was measured by the 2 1 0
pairwise Pearson correlation coefficients and presented in a heatmap. In all analyses for this 2 1 1 small scale pilot study an uncorrected p-value threshold of 0.10 was used as the significance 2 1 2 cutoff. 2 1 3 2 1 4 3. RESULTS: 2 1 5 2 1 6
3.1 Patient Characteristics 2 1 7 2 1 8
Plasma metabolite data were available at baseline and week 12 from 26 patients. The 2 1 9 mean number of therapy sessions attended was 14.0 ± 1.5. To investigate the functional response of the MDD metabolome during receipt of CBT, 2 2 6 we adopted a multivariate approach. Using WGCNA methodology we focused on identifying 2 2 7 modules (or clusters) of metabolites that showed a similar pattern of change from baseline to 2 2 8
week 12. Thus, each module represented metabolite changes (week12/baseline ratios) in the 2 2 9 logarithmic scale. Eight such metabolite modules were identified in which the member 2 3 0 metabolites showed statistically significant strong correlations (mean R 2 ranged between 0.74 2 3 1 and 0.94, all p<0.05 ) amongst each other in their perturbation patterns, and each module was 2 3 2 assigned a unique color. Black, blue, brown, green-yellow, midnight-blue, purple, royal-blue and 2 3 3 yellow were the metabolite modules representing 8, 15, 12, 96, 5, 6, 3 and 9 metabolites, 2 3 4
respectively. The grey module represented 6 metabolites that could not be assigned to any 2 3 5
module. The detected modules were represented by metabolites belonging primarily to the same 2 3 6 metabolite class; this may indicate that these metabolites have a functional relationship to each 2 3 7
other. Additionally, for each module we identified a 'hub' metabolite (also known as a 'driver' 2 3 8 metabolite) that had the maximum number of connections in the module. The hub metabolites 2 3 9
are important and they merit further investigation because they may influence the function of 2 4 0 other metabolites, or even may be significant contributors to the trait of interest. The eight 2 4 1 modules, their hub metabolites, and their major metabolite classes are presented in Next, we evaluated the association between the identified metabolite modules and 2 4 9 changes in HAM-D 17 scores from baseline to week 12. Three metabolite modules were found to 2 5 0 be significantly associated ( R 2 >0.3, at p<0.1) with changes in the symptom severity scores: a) 2 5 1 the purple module containing the short chain acylcarnitines (C3, C4, and C0), α -aminoadipic 2 5 2 acid, and the two amino acids, Glutamate and Proline; b) the yellow module containing the 2 5 3
BCAAs, Isoleucine and Valine, the BCAA-derived C5-carnitine (Isovalerylcarnitine), the 2 5 4
neurotransmitter-related amino acids Tryptophan, Tyrosine, Phenylalanine, Methionine, 2 5 5
Methionine-sulphoxide, and the biogenic amine Sarcosine ; and c) the green-yellow module 2 5 6
containing 96 lipid molecules including the phosphatidylcholines, sphingomyelins, and 2 5 7 acylcarnitines. A heatmap showing the correlations between each of the metabolite modules and 2 5 8
the changes in HAM-D 17 scores is presented in Figure 2 . The correlation coefficients were 2 5 9
moderate, ranging between 0.31 and 0.36 for each of the three modules.
We examined the correlation of each of the metabolite members of the purple, yellow and 2 6 1 green-yellow modules to HAM-D 17 scores. Figure 3A presents a composite plot of the 2 6 2 correlations between the changes of each member-metabolite of the purple module to each other 2 6 3
and also to HAM-D 17 changes. Each of the metabolite changes was negatively associated with 2 6 4 changes in HAM-D 17 , but they were positively correlated to each other. α -aminoadipic acid 2 6 5
showed the strongest correlation to HAM-D 17 changes (R 2 = -0.52, p<7E-06). The BCAA-2 6 6 derived C3-(propionyl) and C4-(butyryl) carnitines were strongly correlated to each other (R 2 = 2 6 7 0.93, p<1.3E-11) as well as to α -aminoadipic acid. C3-carnitine was the hub metabolite in this 2 6 8 module. 2 6 9
Figure 4A presents a similar composite figure for the yellow module. All members were 2 7 0 negatively correlated to HAM-D 17 changes, with the BCAA valine and the known oxidative 2 7 1 stress biomarker methionine sulfoxide perturbations showing the strongest correlations with 2 7 2 HAM-D 17 changes (R 2 < -0.40, p<0.05). All the yellow module metabolites showed strong 2 7 3 positive correlations with each other (mean R 2 = 0.75, range 0.44 -0.93, all p< 0.02) in their 2 7 4 perturbation patterns. Notable were the strong positive correlations between the branched chain 2 7 5 amino acids and methionine, sarcosine, and the neurotransmitter related amino acids 2 7 6 (phenylalanine, tryptophan and tyrosine) indicating that they may be functionally related. Valine 2 7 7
was the hub metabolite for this module. 2 7 8
The members of the 96 lipids-containing green-yellow module also showed strong 2 7 9
correlations amongst each other and also to HAM-D 17 changes. Unlike the amino acids and the 2 8 0 short chain acylcarnitines from the purple and yellow modules, these lipid molecules' changes 2 8 1
were positively associated with HAM-D 17 changes and also to each other (Supplemental figures 2 8 2 1A and 1B).
In univariate linear mixed model analysis, the log2 fold changes of the α -aminoadipic 2 8 4 acid, the branched chain amino acids, isoleucine and valine, methionine-sulfoxide and several of 2 8 5 the phosphatidylcholines, containing long chain fatty acids, from the green-yellow module, were 2 8 6
found to be significantly associated (p<0.10) with the changes in HAM-D 17 scores after adjusting 2 8 7
for age and sex. These findings highlight the potential involvements of mitochondrial energy 2 8 8 metabolism and lipids in the response of depressed patients receiving CBT. Table 3 depicts the 2 8 9
list of metabolites that were significant in univariate models and their associations with 2 9 0 depressive symptom scores (HAM-D 17 ). 2 9 1
To maximize our ability to detect the effects of treatment outcomes, we plotted the mean 2 9 2 trajectories of the metabolites among the CBT remitters (N = 12) and the treatment failures (N = 2 9 3 7), leaving out the patients with intermediate outcomes, consistent with the approach used in 2 9 4
other biomarker studies (Vadodaria et al. 2019; Dunlop, Rajendra, et al. 2017 ). There were 2 9 5
interesting trends among the metabolites in the purple, yellow, and green-yellow modules. In the 2 9 6
green-yellow module, consisting of lipids, ~75% of the phosphatidylcholines were higher at 2 9 7 baseline in the remitters compared to the treatment failures (Supplemental Figure 2) , with some 2 9 8 of them being statistically significant at p<0.10 (PC aa-C30:0, C34:1 C36:2, C36:3, PC ae-2 9 9
C36:0, C38:2). In the purple ( Figure 3B ) and yellow ( Figure 4B ) modules, consisting mostly of 3 0 0 amino acids including BCAAs and the short-chain acylcarnitines, the remitters mostly had lower 3 0 1 baseline levels but showed an upward trend in their metabolite trajectories from baseline to week 3 0 2 12 while the treatment failures all trended to decrease to lower levels post therapy. The limited 3 0 3 sample size, however, precluded detection of statistical significance to these differences in 3 0 4
trajectories.
Using liquid-chromatography coupled to mass-spectrometry analyses, we examined the 3 1 0
biochemical changes that occurred in the plasma of depressed outpatients completing a course of 3 1 1
CBT. Changes in several metabolite modules, containing primarily short-chain acylcarnitines 3 1 2 and α -aminoadipic acid (purple module) as well as branched-chain and neurotransmitter-related 3 1 3
amino acids (yellow module) and lipids (green-yellow module), were significantly associated 3 1 4
with changes in depressive symptom severity over the 12-weeks of CBT treatment. The 3 1 5
metabolites within each module were highly correlated, and therefore it is likely that the 3 1 6 similarity in their perturbations stemmed from their functional relatedness or being members of 3 1 7
the same affected pathways. 3 1 8
Changes in individuals' metabotypes during periods of intense stress, and their return to 3 1 9
the original homeostatic levels upon stress resolution (Ghini et al. 2015) , support the possibility 3 2 0
of identifying metabolomic state markers in MDD. Our analyses found specific amino acids, 3 2 1 acylcarnitines, phosphatidylcholines, and sphingomyelins were associated with the depressed 3 2 2 state and with changes after CBT treatment. Most notably, concentrations of the BCAAs  3  2  3 isoleucine and valine, along with methionine sulfoxide and α -aminoadipic acid, showed strong 3 2 4
inverse correlations with change in depression severity. Conversely, many lipid metabolites were 3 2 5
directly correlated with changes in depression severity. 3 2 6
Alterations in BCAAs have been linked to altered mitochondrial energy metabolism and 3 2 7
have been previously implicated in MDD (Baranyi et al. 2016) The lipid perturbations, especially those of the phosphatidylcholines (consisting of either 3 3 6 diacyl or alkyl-acyl moieties) showed positive correlations to the changes in HAM-D 17 scores. 3 3 7
Phosphatidylcholines are a large class of lipid molecules commonly known as the 3 3 8
glycerophospholipids. They have important functions in membrane stability, permeability, and 3 3 9
signaling. Phosphatidylcholines have been implicated in MDD in several studies. Recently 3 4 0
Knowles et al (Knowles et al. 2017) suggested that a subclass of the phosphatidylcholines (the 3 4 1 ether-phosphatidylcholines) might have a shared genetic etiology with MDD, and thus might be 3 4 2
candidates for improved diagnosis and treatment of depression. Our previous work with 3 4 3 ketamine have implicated these lipids along with acylcarnitines in the mechanism of response to 3 4 4
ketamine (Rotroff et al. 2016) . 3 4 5
These results, suggesting that the metabolites may serve as state markers of depression, 3 4 6 received tentative support from our exploratory contrast of the differential trajectories of the 3 4 7 changes in metabolites between the patients with the clearest treatment outcomes: remitters 3 4 8
versus treatment failures. The BCAAs, their catabolic byproducts, the short chain acylcarnitines, 3 4 9
the lysine metabolite α -aminoadipic acid, and the aromatic amino acids (phenylalanine, tyrosine 3 5 0
and tryptophan) were present at comparatively higher levels at baseline in the treatment failures 3 5 1 compared to the remitters. These findings suggest that metabolic wellbeing may be an important 3 5 2 factor contributing to CBT response. Interestingly, there was a general downward trend in the 3 5 3 trajectories of these metabolites over the course of treatment among the CBT treatment failures, 3 5 4
whereas in the remitters they all exhibited stable or upward trajectories. It is possible that the 3 5 5
differences in metabolic trajectories observed in remitters versus treatment failures to CBT 3 5 6
indicate a state of "metabolic resilience" (Ghini et al. 2015) in the remitters. The two outcome 3 5 7
groups also differed in their metabolomic profiles at baseline, with approximately 75% of the 3 5 8
phosphatidylcholines being elevated in the remitters compared to the treatment failures, 3 5 9
suggesting that levels of these lipid components may serve as moderators of outcome to CBT. It 3 6 0
is also possible that these baseline differences reflect true subtype differences among the MDD 3 6 1 patients that might have a role in treatment selection. Larger scale, longitudinal studies will be 3 6 2 necessary to test these hypotheses. 3 6 3
The primary limitation to this study is the relatively small number of subjects analyzed. 3 6 4
Consequently, testing for the statistical significance of the effects observed was compromised, 3 6 5
particularly for the categorical comparisons of differences by treatment outcome group. The 3 6 6 study also lacked a healthy control group that could have permitted quantification of how far the 3 6 7
observed metabolite concentrations were outside the "normal" ranges. Despite these limtations, 3 6 8
the study is important as an original exploration of the metabolomic changes in depression with a 3 6 9
proven and well-delivered psychotherapy treatment, in the absence of the powerful metabolomic 3 7 0 effects of psychopharmacotherapy. 3 7 1 3 7 2
In summary, this pilot evaluation assessed ~180 metabolites from the Biocrates 3 7 3
Absolute p180 kit that clustered into 8 "co-expression modules" based on their propensities to 3 7 4 change over 12-weeks of treatment with CBT. The results were largely confirmed by additional 3 7 5
univariate analyses of the individual metabolites in the co-expression analyses. Specifically, 3 7 6
BCAAs, methionine sulfoxide, α -aminoadipic acid, and multiple phosphatidylcholines were all 3 7 7
altered in association with changes in the HAM-D 17 scores at a level that equaled or exceeded a 3 7 8 correlation coefficient of 0.4. Hence, these metabolites may represent markers for the depressed 3 7 9
state, and perhaps may act as moderators or mediators for improvement from depression. The 3 8 0 results of this study provide an empirically testable set of hypotheses for MDD, namely the 3 8 1 utility of these metabolites as potential state markers, in order to understand the mechanistic 3 8 2
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FIGURE LEGENDS
Figure 1: Workflow for data analysis.
Figure 2:
A heatmap showing correlations between the metabolite modules and the changes in symptom severity (HAM-D 17 ) scores. Each module represents a number of metabolites that showed strongly correlated perturbation patterns, from baseline to week 12, in response to CBT. The metabolite members of the three modules, purple, yellow and greenyellow, that showed significant association ( R 2 >0.3, at p<0.1) with changes in HAM-D 17 scores are presented in adjacent boxes. 
